New aromataze inhibitor (letrozol) in treatment of advanced breast cancer

Janusz Skowronek

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

4/1999
vol. 3

Send email

Copy url:

abstract:

New aromataze inhibitor (letrozol) in treatment of advanced breast cancer

Janusz Skowronek

Współcz Onkol (1999) 4, 154-155

Online publish date: 2003/08/05

View full text Get citation

Patients with advanced breast cancer constitute 4 to 20% of patients with breast cancer. Results of treatment are still disappointing. Drugs like aromatase inhibitors decrease biosynthesis of estrogens which stymulate tumor growth, they prove to be especially effecive in treatment of advanced breast cancer in postmenopausal women with hormonal-dependent breast cancer.
In this paper the new aromatase inhibitor (letrozol) is described. Indication for treatment, contrindications and adverse experiences are presented. Efficacy of treatment of advanced breast cancer patients with letrozol and others aromatase inhibitors is compared.

keywords:

New aromataze inhibitor (letrozol) in treatment of advanced breast cancer

Janusz Skowronek

aromatase inhibitors, letrozol, advanced breast cancer